


Appl. No. 10/520,284

Submission of an Information Disclosure Statement Dated November 10, 2005



Appl. No : 10/520,284 ✓ Confirmation No.: Unknown
Applicant : Janice Beth Yeved Richman-Eisenstat et al.
Filed : July 25, 2003
Title : Modulation of Mesenchymal Cells Via IGA-Receptors
TC./A.U. : Unknown
Examiner : Unknown

Docket No. : 9157-62
Customer No. : 001059

Honorable Commissioner for Patents
P. O. Box 1450
Alexandria, Virginia 22313-1450

FILING OF AN INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR 1.97 and 1.98, and in recognition of the duty of disclosure set forth in 37 CFR 1.56, Applicant hereby submits an Information Disclosure Statement on Form PTO-1449 containing a listing of publications of which Applicant is aware. Applicant is also submitting the references listed on the Information Disclosure Statement.

All of the patents and publications submitted herewith are in the English language. Accordingly a concise explanation of the relevance of the documents is not required.

The Examiner is requested to indicate consideration of these documents by initialing the appropriate column.

Applicants reserve the right to contest the applicability of any of these documents as prior art against the subject application. If the Examiner has any questions concerning this Information Disclosure Statement, he/she is requested to contact the undersigned. Entry of the enclosed Information Disclosure Statement is believed to be in order and is respectfully requested.

This Information Disclosure Statement is being filed before the issuance of a first official action, and therefore no fees are required. However, please charge our deposit account No. 02-2095 if such a fee is required.

Respectfully submitted,


Janice Beth Yeved Richman-Eisenstat et al.

A handwritten signature in black ink, appearing to read "M. Gravelle". The signature is fluid and cursive, with the first letter of the last name being a large, stylized 'G'.

Micheline Gravelle
Registration No. 40,261

Dated: November 10, 2005
Bereskin & Parr
Box 401, 40 King Street West
Toronto, Ontario, Canada
M5H 3Y2

(416) 364-7311



Complete if Known

Application Number	10/520,284
Filing Date	July 25, 2003
First Named Inventor	Janice B.Y. Richman-Eisenstat et al.
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	9157-62


Sheet	1	of	6
-------	---	----	---

[illegible][illegible]

Date Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Substitute for form 1495B/REMARKS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 6

Complete if Known

Application Number	10/520,284
Filing Date	July 25, 2003
First Named Inventor	Janice B.Y. Richman-Eisenstat et al.
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	9157-62

NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	FERKOL, T. et al., Journal of Clinical Investigation, November 1993, vol. 92, no. 5, 2394-2400.	
	2	FERKOL, T. et al., American Journal of Respiratory and Critical Care Medicine, May 15, 2003, vol. 167, no. 10, 1374-1379.	
	3	MONTENEGRO, V. et al., Current Opinion in Rheumatology 1999 United States, 1999, vol. 11, no. 4, pages 265-272.	
	4	WOLF, H.M. et al., Clinical and Experimental Immunology, 1996, vol. 105, no. 3, pages 537-543.	
	5	LAUNAY, P. et al., J. Biol. Chem., March 12, 1999, 274(11): 7216-25.	
	6	MOSTOV, K.E. et al., Regulation of Protein Traffic in Polarized Epithelial Cells: The Polymeric Immunoglobulin Receptor Model, Cold Spring Harbor Symposia on Quantitative Biology, vol. LX, 1995, 775-781.	
	7	TUFFAHA, A. et al., The Role of Respiratory Viruses in Acute and Chronic Asthma, Clinics in Chest Medicine, vol. 21, no. 2, June 2000.	
	8	HOLGATE, Stephen T., et al., Epithelial-mesenchymal interactions in the pathogenesis of asthma, J. Allergy Clin. Immunology, February 2000, vol. 105, no. 2, part 1, 193-204.	
	9	MESTECKY, J., Mucosal Immunoglobulins, Mucosal Immunology, Chapter 9, 1999, 133-152.	
	10	MOSTOV, K., Immunoglobulin Transport and the Polymeric Immunoglobulin Receptor, Mucosal Immunology, Chapter 12, 1999, 181-211.	
	11	SHEETS, Michael D., Efficient construction of a large nonimmune phage antibody library: The production of high-affinity human single-chain antibodies to protein antigens, Proc. Natl. Acad. Sci., May 1998, vol. 95, pp. 6157-616.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form PTO/SB/08b(08-03)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 6

Complete if Known

Application Number	10/520,284
Filing Date	July 25, 2003
First Named Inventor	Janice B.Y. Richman-Eisenstat et al.
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	9157-62

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	12	DAVIES, Donna E. et al., Airway remodeling in asthma: New insights, J. Allergy Clin. Immunology, February, 2003, vol. 111, no. 2, 215-225.	
	13	HALAYKO, Andrew J. et al., Divergent differentiation paths in airway smooth muscle culture: induction of functionally contractile myocytes, American Physiological Society, 1999, 197-206.	
	14	SCHMIDT, Dunja, et al. Immune mechanisms of smooth muscle hyperactivity in asthma, J. Allergy Clin. Immunol., April 2000, vol. 105, no. 4, 673-682.	
	15	MONTEIRO, Renato, C., et al., J. Exp. Med., March 1990, vol. 171, 597-613.	
	16	OKUTAN, O., et al., Yonsei Med Journal, 2003, vol. 44, no. 2, 242-248.	
	17	UNGER, S., Am J. Pathol., February, 2003, 162(2): 547-55.	
	18	ANTONISSEN, L.A., et al., Histamine Pharmacology in Airway Smooth Muscle from a Canine Model of Asthma, The Journal of Pharmacology and Experimental Therapeutics, 1980, vol. 213, no. 1, 150-155.	
	19	HALAYKO, Andrew J., et al., Markers of airway smooth muscle cell phenotype, The American Physiological Society, 1996, 1040-1051.	
	20	DEO, Yashwant M., et al., The Journal of Immunology, 1998. 1677-1686.	
	21	ACKERMANN, L.W., et al., The Journal of Immunology, 1999, 162: 5112-5118.	
	22	ALBRECHTSEN, M., et al., Characterization of the IgA receptor from human polymorphonuclear leucocytes, Immunology, 1988, vol. 64, 201-205.	


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 6

Complete if Known

Application Number	10/520,284
Filing Date	July 25, 2003
First Named Inventor	Janice B.Y. Richman-Eisenstat et al.
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	9157-62

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	23	HERBELIN, Patry A., et al., Immunology, 1995, vol. 86, 1-5.	
	24	BELL, Dianne Y., et al., Plasma Proteins of the Bronchoalveolar Surface of the Lungs of Smokers and Nonsmokers, Bronchoalveolar Proteins, 1981.	
	25	CHILDERS, Noel K. et al., Molecular Mechanisms of Immunoglobulin A Defense, Annu. Rev. Microbiol., 1989, 43:503-36.	
	26	CHOY, Ernest H.S. et al., Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis, The New England Journal of Medicine, vol. 344: 907-916.	
	27	GIOUD-PAQUET, M. et al., Annals of the Rheumatic Diseases, 1987, vol. 46, 65-71.	
	28	HU, Qinghua et al., The Journal of Biological Chemistry, November 26, 1999, vol. 274, no. 48, 33995-33998.	
	29	HOUSSEN, Dhiya A., Clinical Significance of IgA Rheumatoid Factor Subclasses in Rheumatoid Arthritis, The Journal of Rheumatology, 1997, 24:11, 2119-2122.	
	30	JENKINS, John K., et al., The Pathogenesis of Rheumatoid Arthritis: A Guide to Therapy, The American Journal of the Medical Sciences, April 2002, vol. 323, no. 4, 171-180.	
	31	JOHANSEN, Finn-Eirik et al., The Journal of Immunology, 2001, 167: 5185-5192.	
	32	JONSSON, T. et al., Rheumatol. Int., 1992, 12:111-113.	
	33	JORGENSEN, C., et al., Clinical and Experimental Rheumatology, 1996, vol. 14, 301-304.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)


Sheet

5

of

6

NOV 14 2005



Complete if Known

Application Number	10/520,284
Filing Date	July 25, 2003
First Named Inventor	Janice B.Y. Richman-Eisenstat et al.
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	9157-62

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	34	JONSSON, T. et al., Scand. J. Rheumatol., 1995, vol. 24, 372-375.	
	35	RITCHLIN, Christopher, Fibroblast biology Effector signals released by the synovial fibroblast in arthritis, Arthritis Res., 2000, vol.2 no. 5, 356-360.	
	36	KERR, Michael A., et al., Mucosal Immunology, Chapter 13, 1999, 213-224.	
	37	LOUIS, Renaud et al., Am. J. Respir. Crit. Care Med., 1997, vol. 155, 466-472.	
	38	MACKENZIE, Simon J., et al., Biochem. J., 1995, vol. 306, 519-523.	
	39	MALISZEWSKI, Charles R., Expression Cloning of a Human Fc Receptor for IgA, J. Exp. Med., December 1990, vol. 172, 1665-1672.	
	40	MORTON, H. Craig, et al., The Journal of Biological Chemistry, December 15, 1995, vol. 270, no. 50, 29781-29787.	
	41	MORTON, H. Craig, et al., Critical Reviews in Immunology, 1996, vol. 16, 423-440.	
	42	NAHM, D.H., et al., Clinical and Experimental Allergy, 1997, vol. 27, 676-681.	
	43	NAHM, D.H., et al., Eur. Respir. J., 1998, 12: 540-545.	
	44	OTTEN, H.G. et al., Arthritis and Rheumatism, July 1991, vol. 34, no. 7, 831-839.	


Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 6 of 6

Complete if Known

Application Number	10/520,284
Filing Date	July 25, 2003
First Named Inventor	Janice B.Y. Richman-Eisenstat et al.
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	9157-62

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	45	PAI, S. et al., Scand. J. Rheumatol., 1998, 27: 252-6.	
	46	PISKURICH, J.F. et al., Molecular Cloning of the Mouse Polymeric Ig Receptor, The American Association of Immunologists, 1995, 1735-1747.	
	47	SCHROHENLOHER, Ralph, E. et al., Arthritis and Rheumatism, October 1986, vol. 29, no. 10, 1194-1202.	
	48	SCOTT, D.L. et al., Long-Term Outcome of Treating Rheumatoid Arthritis: Results after 20 years, The Lancet, May 16, 1987, 1108-1111.	
	49	SHEN, Li, Journal of Leukocyte Biology, April 1992, vol. 51, 373-378.	
	50	STEWART, Wilson W., et al., Journal of Leukocyte Biology, October 1994, vol. 56, 481-487.	
	51	SYMERSKY, Jindrich et al., Molecular Immunology, 2000, vol. 37, 133-140.	
	52	TEITSSON, Ingvar et al., Annals of the Rheumatic Diseases, 1984, vol. 43, 673-678.	
	53	VALERIUS, Thomas et al., Blood, December 1, 1997, vol. 90, no. 11, 4485-4492.	
	54	YEAMAN, G.R. et al., Clin. Exp. Immunol., 1987, vol. 68, 200-208.	
	55	JONSSON, T. et al., Rheumatol. Int., 1998, vol. 18, 119-122.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.